Liver failure after major liver resection: Risk assessment by using preoperative gadoxetic acid-enhanced 3-T MR imaging

Radiology

Volumn 269, Issue 3, 2013, Pages 777-786

  Wibmer, Andreas ^a   Prusa, Alexander M ^a   Nolz, Richard ^a   Gruenberger, Thomas ^a   Schindl, Martin ^a   Ba Ssalamah, Ahmed ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GADOXETIC ACID;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER FAILURE; LIVER PARENCHYMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; RELATIVE LIVER ENHANCEMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BILIRUBIN; BIOLOGICAL MARKERS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATECTOMY; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROTHROMBIN TIME; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84890045871     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13130210     Document Type: Article

References (51)

1. Schreckenbach T, Liese J, Bechstein WO, Moench C. Posthepatectomy liver failure. Dig Surg 2012;29(1):79-85.
2. Breitenstein S, DeOliveira ML, Raptis DA, et al. Novel and simple preoperative score predicting complications after liver resection in noncirrhotic patients. Ann Surg 2010; 252(5):726-734.
3. Schindl MJ, Millar AM, Redhead DN, et al. The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg 2006;243(4):507-514.
4. Paugam-Burtz C, Janny S, Delefosse D, et al. Prospective validation of the "fifty-fifty" criteria as an early and accurate predictor of death after liver resection in intensive care unit patients. Ann Surg 2009;249(1):124-128.
5. van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 2008;28(6): 767-780.
6. Lock JF, Reinhold T, Malinowski M, Pratschke J, Neuhaus P, Stockmann M. The costs of postoperative liver failure and the economic impact of liver function capacity after extended liver resection-a single-center experience. Langenbecks Arch Surg 2009; 394(6):1047-1056.
7. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg 2012; 29(1):6-17.
8. Hoekstra LT, de Graaf W, Nibourg GA, et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013;257(1):27-36.
9. Lam CM, Fan ST, Lo CM, Wong J. Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test. Br J Surg 1999; 86(8):1012-1017.
10. Kwon AH, Ha-Kawa SK, Uetsuji S, Inoue T, Matsui Y, Kamiyama Y. Preoperative determination of the surgical procedure for hepatectomy using technetium-99m-galactosyl human serum albumin (99mTc-GSA) liver scintigraphy. Hepatology 1997;25(2):426-429.
11. Sawada T, Kita J, Nagata H, Shimoda M, Kubota K. Hepatectomy for metastatic liver tumor in patients with liver dysfunction. Hepatogastroenterology 2007; 54(80):2306-2309.
12. Wong JS, Wong GL, Chan AW, et al. Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes. Ann Surg 2013;257(5):922-928.
13. Ramacciato G, D'Angelo F, Baldini R, et al. Hepatocellular carcinomas and primary liver tumors as predictive factors for postoperative mortality after liver resection: a meta-analysis of more than 35, 000 hepatic resections. Am Surg 2012;78(4):456-467.
14. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255(3):824-833.
15. Dahlqvist Leinhard O, Dahlström N, Kihlberg J, et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 2012;22(3):642-653.
16. Okada M, Ishii K, Numata K, et al. Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function? Hepatobiliary Pancreat Dis Int 2012;11(3):307-313.
17. Wibmer A, Aliya Q, Steininger R, et al. Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 2012;47(6):353-358.
18. Clément O, Mühler A, Vexler V, Berthezène Y, Brasch RC. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992;27(8):612-619.
19. Ni Y, Marchal G, Lukito G, Yu J, Mühler A, Baert AL. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 1994;190(3):753-758.
20. Sonoda A, Nitta N, Ohta S, et al. The Possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans. Acad Radiol 2011;18(4):525-529.
21. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007;42(4):242-247.
22. Goshima S, Kanematsu M, Watanabe H, et al. Gd-EOB-DTPA-enhanced MR imaging: compariprediction of hepatic fibrosis stages using liver contrast enhancement index and liverto-spleen volumetric ratio. J Magn Reson Imaging 2012;36(5):1148-1153.
23. Norén B, Forsgren MF, Dahlqvist Leinhard O, et al. Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. Eur Radiol 2013;23(1):174-181.
24. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 2011;259(1):142-150.
25. Kanki A, Tamada T, Higaki A, et al. Hepatic parenchymal enhancement at Gd-EOBDTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012;30(3):356-360.
26. Tamada T, Ito K, Sone T, Kanki A, Sato T, Higashi H. Gd-EOB-DTPA enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 2011;80(3):e207-e211.
27. Kim HJ, Kim BS, Kim MJ, et al. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. J Magn Reson Imaging 2013;37(4):903-908.
28. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010;31(2):356-364.
29. Chernyak V, Kim J, Rozenblit AM, Mazzoriol F, Ricci Z. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors. J Magn Reson Imaging 2011;34(2):301-309.
30. Kang Y, Lee JM, Kim SH, Han JK, Choi BI. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 2012;264(3):751-760.
31. Higaki A, Tamada T, Sone T, et al. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging 2012;30(5):689-693.
32. Cho SH, Kang UR, Kim JD, Han YS, Choi DL. The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study. Eur J Radiol 2011;80(2):e195-e200.
33. Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg 2013;257(3):377-382.
34. Balzan S, Belghiti J, Farges O, et al. The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005;242(6):824-828; discussion 828-829.
35. Rahbari NN, Reissfelder C, Koch M, et al. The predictive value of postoperative clinical risk scores for outcome after hepatic resection: a validation analysis in 807 patients. Ann Surg Oncol 2011;18(13):3640-3649.
36. Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011;253(4):745-758.
37. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007;245(6):923-930.
38. Bachellier P, Rosso E, Pessaux P, et al. Risk factors for liver failure and mortality after hepatectomy associated with portal vein resection. Ann Surg 2011;253(1):173-179.
39. Lang H, Sotiropoulos GC, Frühauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg 2005;241(1): 134-143.
40. Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg 2009;33(4):797-803.
41. Mayo SC, Shore AD, Nathan H, et al. Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) 2011;13(7):473-482.
42. Berger-Kulemann V, Schima W, Baroud S, et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol 2012;38(8): 670-676.
43. Kim YK, Park G, Kim CS, Yu HC, Han YM. Diagnostic efficacy of gadoxetic acidenhanced MRI for the detection and characterisation of liver metastases: compareson with multidetector-row CT. Br J Radiol 2012;85(1013):539-547.
44. Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149(5):713-724.
45. Loehrer AP, House MG, Nakeeb A, Kilbane EM, Pitt HA. Cholangiocarcinoma: are North American surgical outcomes optimal? J Am Coll Surg 2013;216(2):192-200.
46. Kamiyama T, Nakanishi K, Yokoo H, et al. Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010;211(4):443-449.
47. Kennedy TJ, Yopp A, Qin Y, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009;11(5):445-451.
48. Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004;10(2 Suppl 1):S39-S45.
49. Yang T, Zhang J, Lu JH, Yang GS, Wu MC, Yu WF. Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 2011;35(9):2073-2082.
50. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356(15):1545-1559.
51. Morita K, Namimoto T, Awai K, et al. Enhancement effects of hepatic dynamic MR imaging at 3.0 T and 1.5 T using gadoxetic acid in a phantom study: comparison with gadopentetate dimeglumine. Magn Reson Med 2011;66(1):213-218.